Neuland Laboratories

Neuland Laboratories Debt/EBITDA

The Total Debt to EBITDA Ratio of Neuland Laboratories (NEULANDLAB.NS) as of Nov 16, 2026 is 0.62. In the previous year, Total Debt to EBITDA Ratio was 0.47 — a change of 31.90% (higher).

Debt/EBITDA

0.62

YoY

31.90%

Last updated:

Total Debt to EBITDA Ratio of Neuland Laboratories is 2026 0.62 . Total Debt to EBITDA Ratio of Neuland Laboratories was 2025 0.47 . It decreases by 31.90% higher compared to the previous year.

The Neuland Laboratories Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2019
3.60 INR
Jan 1, 2020
2.51 INR
Jan 1, 2021
1.22 INR
Jan 1, 2022
1.66 INR
Jan 1, 2023
0.45 INR
Jan 1, 2024
0.20 INR
Jan 1, 2025
0.47 INR
Jan 1, 2026
0.62 INR
The Neuland Laboratories Debt/EBITDA history
YEARDebt/EBITDAYoY
0.62+31.90%
0.47+131.51%
0.20-54.37%
0.45-73.03%
1.66+36.00%
1.22-51.45%
2.51-30.13%
3.60-41.28%
6.13+242.77%
1.79-14.93%
2.10-20.57%
2.65-4.28%
2.76—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuland Laboratories Stock analysis

What does Neuland Laboratories do? Neuland Laboratories Ltd. generates revenue through the manufacture and export of bulk pharmaceutical ingredients and intermediates for the generics industry. The company operates in a single segment focused on active pharmaceutical ingredients (APIs) and allied services, with two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, and Labetalol, which are supplied to both domestic and international markets. The firm provides end-to-end chemistry solutions for the pharmaceutical industry, covering synthesis of library compounds, NCEs, and advanced intermediates across clinical and commercial stages. The company's primary customers are pharmaceutical firms requiring APIs and intermediates for generic drugs, with a focus on global markets. Neuland Laboratories Ltd. serves as a solution provider for chemistry needs, offering services from early-stage development to commercial production. The business model emphasizes tailored manufacturing services under CMS, alongside standardized GDS products, catering to the full lifecycle of pharmaceutical development and production. Revenue streams are derived from the sale of specific APIs like Levetiracetam and Mirtazapine, as well as custom manufacturing services for complex chemical processes. The firm's dual verticals allow it to address diverse market demands, with GDS targeting cost-effective generic drug production and CMS focusing on specialized, high-value manufacturing solutions for pharmaceutical clients. Neuland Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuland Laboratories stock

Total Debt to EBITDA Ratio of Neuland Laboratories is 0.62 in 2026.

Total Debt to EBITDA Ratio of Neuland Laboratories changed from 0.47 to 0.62, representing a 31.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Neuland Laboratories since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Neuland Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Neuland Laboratories

All Key Metrics — Neuland Laboratories